ARTICLE
15 May 2026

DOT Stance Firm: Medical Marijuana Does Not Excuse Positive Drug Test Results

JL
Jackson Lewis P.C.

Contributor

Focused on employment and labor law since 1958, Jackson Lewis P.C.’s 1,100+ attorneys located in major cities nationwide consistently identify and respond to new ways workplace law intersects business. We help employers develop proactive strategies, strong policies and business-oriented solutions to cultivate high-functioning workforces that are engaged, stable and diverse, and share our clients’ goals to emphasize inclusivity and respect for the contribution of every employee.
The Department of Transportation’s Office of Drug and Alcohol Policy and Compliance published answers on May 15, 2026, regarding the rescheduling of certain medical marijuana products to Schedule III...
United States Employment and HR
Kathryn Russo’s articles from Jackson Lewis P.C. are most popular:
  • in United States
  • with readers working within the Healthcare and Retail & Leisure industries
Jackson Lewis P.C. are most popular:
  • within Energy and Natural Resources topic(s)
  • with Senior Company Executives and HR

The Department of Transportation’s Office of Drug and Alcohol Policy and Compliance published answers on May 15, 2026, regarding the rescheduling of certain medical marijuana products to Schedule III of the Controlled Substance Act (CSA) by the Department of Justice (DOJ).

By Order dated April 22, 2026, the DOJ immediately placed all FDA-approved marijuana products and marijuana products regulated by a state medical marijuana license in Schedule III of the CSA. DOT regulations require that covered employers test for marijuana and make testing positive for marijuana disqualifying. Since medical marijuana products were placed in Schedule III, questions have arisen as to how medical marijuana should be addressed for DOT-regulated employees.

As stated on the ODAPC website:

QUESTION:

Recently, the Drug Enforcement Administration (DEA) issued an order (Order) that reclassified FDA-approved drug products derived from marijuana and marijuana products regulated by a State medical marijuana license from Schedule I to Schedule III drugs under the Controlled Substances Act (CSA). When reviewing a laboratory reported marijuana positive drug test result, can a Medical Review Officer (MRO) deem the test a “negative” if the employee alleges the positive resulted from consuming a State licensed marijuana product?

ANSWER:

  • No. Currently, there is no instance when the MRO could verify a laboratory-confirmed marijuana positive drug test result as “negative” when an employee claims the positive was caused by a State licensed marijuana product.
  • Even after rescheduling, State-dispensed marijuana does not constitute an FDA-approved drug. Without FDA approval for a controlled substance, it cannot be prescribed.
  • A “legitimate medical explanation” requires use of a legally prescribed controlled substance in compliance with Federal laws governing such a prescription. 49 CFR §§ 40.137(a); 40.141(b).
  • Although the MRO may be presented with documentation such as State-issued medical marijuana cards, physician recommendations or certifications, or dispensary records or receipts, these documents do not satisfy part 40 requirements for a “legitimate medical explanation.”
  • Marijuana use under State marijuana programs or other non-prescription sources do not qualify as a “legitimate medical explanation” under 49 CFR § 40.137(a). In addition, marijuana use is not compatible with safety-sensitive functions.

DOT-regulated employers should continue to test for marijuana in accordance with DOT drug and alcohol testing regulations. State-issued medical marijuana cards and licenses do not excuse positive marijuana drug test results. Please contact a Jackson Lewis attorney with any questions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More